$-0.40 EPS Expected for InflaRx N.V. (IFRX); Public Sector Pension Investment Board Increased By $36.00 Million Its Praxair (Put) (PX) Holding




August 2, 2018 – By Rhonda Roth

Praxair, Inc. (NYSE:PX) Logo

Public Sector Pension Investment Board increased Praxair Inc (Put) (PX) stake by 250% reported in 2018Q1 SEC filing. Public Sector Pension Investment Board acquired 250,000 shares as Praxair Inc (Put) (PX)’s stock rose 0.80%. The Public Sector Pension Investment Board holds 350,000 shares with $50.51 million value, up from 100,000 last quarter. Praxair Inc (Put) now has $47.55B valuation. The stock decreased 1.21% or $2.02 during the last trading session, reaching $165.48. About 1.45 million shares traded or 3.30% up from the average. Praxair, Inc. (NYSE:PX) has risen 19.06% since August 2, 2017 and is uptrending. It has outperformed by 6.49% the S&P500. Some Historical PX News: 08/03/2018 Linde: Completion of Praxair Deal Still Expected in 2H; 25/04/2018 – LINDE AG LING.DE – IN EVENT OF SUCCESSFUL COMPLETION, LINDE INTERMEDIATE HOLDING AG IS EXPECTED TO HOLD APPROX 92 % IN LINDE AG; 20/04/2018 – Praxair Signs Long-Term Agreement to Supply Samsung Electro-Mechanics in Busan, South Korea; 08/03/2018 – LINDE LING.DE CEO SAYS STILL BELOW 3.7 BLN SALES THRESHOLD OF POTENTIAL DIVESTITURES, AHEAD OF PRAXAIR MERGER; 17/04/2018 – Praxair Begins Supplying Hydrogen to Marathon Petroleum’s Louisiana Refinery; 27/04/2018 – Proposed Business Combination Between Praxair, Inc. and Linde AG Receives CFIUS Clearance, Satisfying a Closing Condition; 08/03/2018 – LINDE AG LING.DE – COMPLETION OF MERGER WITH PRAXAIR STILL PLANNED FOR SECOND HALF OF 2018; 04/05/2018 – LINDE: PRAXAIR REGULATORY CONDITIONS IN CANADA SATISFIED; 08/03/2018 – LINDE LING.DE , PRAXAIR PX.N HAVE ASKED FOR FIRST-ROUND BIDS BY END-MARCH FOR PLANNED DIVESTITURES; 26/04/2018 – CORRECT: PRAXAIR CALL CONCLUDES

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.40 EPS on August, 16.After having $-0.49 EPS previously, InflaRx N.V.’s analysts see -18.37% EPS growth. The stock increased 0.82% or $0.25 during the last trading session, reaching $30.82. About 14,923 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since August 2, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $790.91 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Investors sentiment decreased to 0.98 in 2018 Q1. Its down 0.08, from 1.06 in 2017Q4. It turned negative, as 57 investors sold PX shares while 300 reduced holdings. 93 funds opened positions while 257 raised stakes. 232.95 million shares or 0.44% less from 233.99 million shares in 2017Q4 were reported. Madison Invest Inc holds 484,583 shares. Greenleaf reported 8,000 shares. Kanawha Cap Limited Liability Com holds 0.05% or 2,360 shares. Massachusetts-based Adage Partners Gp Lc has invested 0.13% in Praxair, Inc. (NYSE:PX). Manufacturers Life The invested 0.07% in Praxair, Inc. (NYSE:PX). Chesley Taft Associate Ltd Liability Company holds 0.31% or 24,478 shares in its portfolio. Btim Corporation reported 181,494 shares. Talara Cap Mgmt Ltd Llc owns 44,397 shares. Salem Inv Counselors Incorporated owns 2,000 shares for 0.03% of their portfolio. Spinnaker Trust has 5,344 shares. Hl Financial Services Ltd Llc invested in 0.01% or 3,056 shares. Amp Cap Investors invested in 0.07% or 88,125 shares. Vanguard Grp Inc holds 22.08M shares or 0.14% of its portfolio. Lodestar Invest Counsel Ltd Liability Co Il, Illinois-based fund reported 1,950 shares. Cibc Asset Management Incorporated has 32,367 shares.

More news for Praxair, Inc. (NYSE:PX) were recently published by: Seekingalpha.com, which released: “Praxair, Inc. 2018 Q2 – Results – Earnings Call Slides” on July 26, 2018. Seekingalpha.com‘s article titled: “Praxair (PX) Q2 2018 Results – Earnings Call Transcript” and published on July 26, 2018 is yet another important article.

Public Sector Pension Investment Board decreased O Reilly Automotive Inc New (NASDAQ:ORLY) stake by 8,359 shares to 4,669 valued at $1.16M in 2018Q1. It also reduced Aes Corp (NYSE:AES) stake by 126,401 shares and now owns 36,903 shares. Darden Restaurants Inc (NYSE:DRI) was reduced too.

Praxair, Inc. (NYSE:PX) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *